Hutchmed has completed enrollment in its China Phase 3 SANOVO trial, evaluating the combination of savolitinib (Orpathys) and osimertinib (Tagrisso) as a first-line treatment for patients with EGFR-mutated, MET-overexpressing non-small cell lung cancersmall cell lung cancer (NSCLC). Topline results are expected in the second half of 2026.
This trial represents a pivotal moment for Hutchmed’s partnership with AstraZeneca, which co-develops and commercializes savolitinib. While Tagrisso is already a standard of care in EGFR-mutated NSCLC, the addition of savolitinib, a selective MET inhibitor, aims to address a crucial resistance mechanism that frequently emerges. This strategy underscores the growing emphasis on combination therapies to maximize efficacy and delay disease progression in oncology.
The SANOVO trial builds on the positive data seen in previous studies like TATTON, SAVANNAH, and SACHI, which have explored this combination in later-line settings. The SACHI trial in particular led to approval in China for the savolitinib-Tagrisso combination in patients with EGFR-mutated, MET-amplified NSCLC who had progressed on prior EGFR TKI therapy. Shifting focus to the first-line setting represents an ambitious but logical expansion play, potentially capturing a larger patient population and securing earlier market share.
This development comes as the oncology field grapples with increasing complexity in both trial design and treatment regimens. The use of biomarkers like MET overexpression requires sophisticated diagnostic capabilities at research sites and further complicates patient stratification. While savolitinib/Tagrisso offers a chemotherapy-free option, its success hinges on reliable biomarker testing and timely diagnosis. The ongoing SAFFRON trial, a global Phase 3 study in the later-line setting, will also play a crucial role in shaping the global regulatory strategy for this combination.
The outcome of SANOVO has significant implications for Hutchmed, AstraZeneca, and the broader oncology community. Positive results could reshape the first-line treatment landscape for EGFR-mutated NSCLC, particularly in China, where MET overexpression rates are higher. However, questions remain about the optimal biomarker cutoff for MET overexpression and the long-term safety and efficacy of this combination. Further, the broader trend toward personalized medicine based on tumor profiling adds layers of complexity to trial operations, requiring close coordination between diagnostic developers, research sites, and regulatory authorities. Investors and industry observers should monitor these developments closely to understand the evolving role of targeted therapies and companion diagnostics in precision oncology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
